Atossa Therapeutics, Inc. (ATOS)

$1.04

-0.05 (-4.59%)
Rating:
Recommendation:
Neutral
Symbol ATOS
Price $1.04
Beta 1.992
Volume Avg. 1.80M
Market Cap 131.689M
Shares () -
52 Week Range 0.84-7.15
1y Target Est -
DCF Unlevered ATOS DCF ->
DCF Levered ATOS LDCF ->
ROE -3438.67% Strong Sell
ROA -3493.70% Strong Sell
Operating Margin -
Debt / Equity 1.72% Neutral
P/E -
P/B 0.97 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ATOS news


Dr. Steven Quay
Healthcare
Biotechnology
NASDAQ Capital Market

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.